Payment reform in the US is progressing considerably, but more transparency is necessary in order to change payment for the better in the United States, said Elizabeth Mitchell, president and CEO of the Network for Regional Healthcare Improvement.
Payment reform in the US is progressing considerably, but more transparency is necessary in order to change payment for the better in the United States, said Elizabeth Mitchell, president and CEO of the Network for Regional Healthcare Improvement.
Transcript (slightly modified)
How do you see the pace of payment reform moving?
I think there is considerable momentum for change, at the regional level, at the national level, and across both the public and private sectors. I think the US Department of Health and Human Services (HHS) has been an incredible leader in driving payment reform, but I’m also seeing the commercial sector health plans, employers and providers, get increasingly ready for transformative change. So I see a lot of momentum and a lot of movement.
How closely intertwined is transparency with a value- and performance-based healthcare system?
Well, I think transparency is absolutely necessary but insufficient. I actually think Congress presumed that there was transparent information available when they passed MACRA [Medicare Access and CHIP Reauthorization Act] because you can’t pay for value if you don’t have any way to define it.
So without transparent performance information we’re going to have a very hard time not only changing payment, but evaluating the impact of that. I think there is going to be increasing demand from those moving towards value payment to really have some way to learn what’s happening, to set targets, to set priorities, and then to evaluate impact.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More